Janssen COVID-19 Vaccine and Thrombosis with Thrombocytopenia Syndrome (TTS): Update for Clinicians

Having trouble viewing? View this as a webpage

April 23, 2021
vaccineheader

Johnson & Johnson/Janssen COVID-19 Vaccine and Thrombosis with Thrombocytopenia Syndrome (TTS): Update for Clinicians

 

You may participate in this COCA Call via Zoom

Overview

This COCA Call will present the latest evidence on thrombosis with thrombocytopenia syndrome (TTS) after administration of the Johnson & Johnson/Janssen COVID-19 vaccine. Speakers will discuss information on TTS and updated vaccine recommendations.

 

If you are unable to attend the live COCA Call, the recording will be available for viewing on the COCA Call webpage a few hours after the live event ends.

 

The slide set will be available under "Call Materials" on the COCA Call webpage the day of the call.

 

Continuing Education (CE) will not be provided for this call.

 

Advanced registration is not required.

 

Date: Tuesday, April 27, 2021

 

Time: 2:00 pm - 3:00 pm (ET)

 

A few minutes before the webinar starts, please click on the Zoom link below to join: https://www.zoomgov.com/j/

1601111927?pwd=UTliM1BEWnJ0Skp

KUzZnZUVDTVBxUT09

 

Or one-tap mobile: 

US: +16692545252,,1601111927#,,,,*358595#

or

+16468287666,,1601111927#,,,,*358595#

 

Or Telephone: Dial (for higher quality, dial a number based on your current location): 

US: +1 669 254 5252 or

+1 646 828 7666 or

+1 551 285 1373 or

+1 669 216 1590

 

Webinar ID: 160 111 1927

 

Passcode:358595

 

International numbers available: https://www.zoomgov.com/u/avXUsqKMa

COCA Call Objectives

 

At the conclusion of the session, the participant will be able to accomplish the following—
  1. Cite background information on the topic covered during the presentation.
  2. Discuss CDC’s role in the topic covered during the presentation.
  3. Describe the topic’s implications for clinicians.
  4. Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
  5. Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of healthcare providers.

 

Presenters

Sara Oliver, MD

LCDR, U.S. Public Health Service

Co-lead, Advisory Committee for Immunization Practices COVID-19 Vaccines Work Group

COVID-19 Response

Centers for Disease Control and Prevention

 

Tom Shimabukuro, MD, MPH, MBA

CAPT, U.S. Public Health Service

Vaccine Safety Team Lead

COVID-19 Response

Centers for Disease Control and Prevention